-
The Chinese medicine industry welcomes favorable policies, and new drugs will be launched at an accelerated pace
Time of Update: 2022-04-15
[Pharmaceutical Network Market Analysis] In order to encourage the innovation of traditional Chinese medicine and promote the development of traditional Chinese medicine, the state has issued a series of policy measures in recent years .
-
Next week, a new pharmaceutical stock will be subscribed for, focusing on APIs and preparations!
Time of Update: 2022-04-15
7424 million yuan respectively, with a three-year compound annual growth rate of net profit attributable to the parent company of 10.
54%; the company's net profit attributable to the parent was 34 million yuan, a year-on-year growth rate of 2.
-
Pharmaceutical companies actively deploy the API business and build the integrated advantage of API preparations
Time of Update: 2022-04-15
[Pharmaceutical Network Market Analysis] In recent years, under the refined division of labor in the global pharmaceutical industry, as the upstream of chemical preparations, the pharmaceutical intermediates and chemical API industries have achieved rapid development .
-
The market of traditional Chinese medicine continues to improve, and these companies are worthy of attention
Time of Update: 2022-04-15
Among them, it is worth mentioning that the "14th Five-Year Plan for National Drug Safety and Promotion of High-Quality Development" jointly issued by the State Drug Administration and other 8 departments earlier clearly proposed that new steps should be taken in the inheritance, innovation and development of traditional Chinese medicine.
-
API companies are accelerating the expansion of production capacity, which is having a positive impact on the pharmaceutical machine industry
Time of Update: 2022-04-15
It is planned to build a new production line project with an annual output of 308 tons of characteristic raw materials and 200 million tablets of anti-tumor preparations in the Cangshan industrial agglomeration area in Tiantai .
-
The field of oncology has become a decisive "highland" for a large number of multinational pharmaceutical companies
Time of Update: 2022-04-15
From the perspective of the clinical pipelines of major pharmaceutical companies, tumors are also the focus of new drug research and development .
-
Under the continuous transformation and upgrading of the pharmaceutical industry, personnel changes will become more frequent
Time of Update: 2022-04-15
In addition to AstraZeneca, many multinational pharmaceutical companies have also undergone major personnel adjustments this year: for example, the head of the Novartis Oncology Hematology Division resigned; the position of the head of the Takeda Oncology Division was finally settled after 2 months of vacancy ; Fresenius Kabi China changed its chief financial officer; Abbott's global vice president resigned, etc.
-
my country has entered a critical period of pharmaceutical innovation-driven transformation, and basic research is the source
Time of Update: 2022-04-15
Facing the future, my country needs to continuously promote the innovation of the pharmaceutical industry, such as improving the research and development of original and high clinical value products and the strategy of going overseas.
-
The ADC field has entered a stage of rapid development, and target competition has become the key
Time of Update: 2022-04-15
[Pharmaceutical Network Market Analysis] Recently, the CDE website showed that AstraZeneca/Daisankyo’s HER2-targeting antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) was declared for listing in China, with unknown indications .
In addition, Enhertu is the first ADC drug approved by the FDA for the treatment of HER2-positive gastric cancer .
-
Cell gene therapy may take over biopharmaceuticals in the future, bringing new growth points to the pharmaceutical machinery industry
Time of Update: 2022-04-15
[Pharmaceutical Network Market Analysis] In recent years, with the rapid development of biopharmaceutical technology, the continuous increase in R&D investment of pharmaceutical companies, and the support of a series of favorable policies, superimposed on the impact of the epidemic, China's biopharmaceutical industry has developed rapidly.
-
In the first half of the year, the market of Chinese medicinal materials was still at a high level, and the prices of a large number of varieties continued to rise.
Time of Update: 2022-04-15
According to relevant data, among the 1,445 varieties monitored by the market, there were 55 varieties of Chinese medicinal materials whose prices rose in March .
-
How should local new drugs go overseas?
Time of Update: 2022-04-15
Judging from the achievements of local new drugs in the process of going overseas, there are currently 5 local innovative drugs that have been successfully approved abroad, including the prescription drug Kanglaite injection for the treatment of cancer, BeiGene's zanubrutinib, and Frontier Bio's Aibo Weitai, Chidamide from Microchip Bio, and Prokalutamide from Kintor Pharmaceuticals, etc.
-
Promoting the intelligentization of pharmaceutical equipment has become a new hot spot in the pharmaceutical machine industry
Time of Update: 2022-04-15
According to the author's understanding, in recent years, under the new situation of the continuous development of the pharmaceutical industry and the accelerated technological change, more and more pharmaceutical equipment companies have vigorously developed in the direction of "unmanned, less humanized, and intelligent" .
-
Two more pharmaceutical companies have reviewed it, and the market war for oral hypoglycemic drugs is intensifying
Time of Update: 2022-04-15
But at the same time, with the increased investment in research and development of enterprises, accelerated drug approval and review, and the support of capital, news of the listing of hypoglycemic drugs in the domestic market has continued to spread in recent years .
-
The "14th Five-Year" Chinese medicine development plan deploys ten key tasks, and the industry development will usher in qualitative changes
Time of Update: 2022-04-15
Analysts said that the introduction of the "14th Five-Year Plan" for traditional Chinese medicine will promote the development of the industry and usher in a qualitative change .
-
In 2030, the domestic in vitro diagnostic market will reach 288.2 billion yuan, and the space to replace the import of high-end production equipment is to be opened
Time of Update: 2022-04-15
It is understood that in the medical and health field, the main product of Kerui Technology is the automatic filling line equipment for in vitro diagnostic reagents (IVD), but it currently accounts for a small amount of the company's overall revenue .
-
A number of pharmaceutical stocks hit the daily limit, focusing on raw materials, traditional Chinese medicine and other sectors
Time of Update: 2022-04-15
In the first three quarters of 2021, the company achieved operating income of 969 million yuan, a year-on-year increase of 4.
69%; net profit attributable to shareholders of listed companies was 128 million yuan, a year-on-year increase of 26.
-
32 senior executives of pharmaceutical companies resigned due to personal reasons, the industry: or affected by the expansion of centralized procurement
Time of Update: 2022-04-15
issued the "Notice on Submitting the Purchase Data Related to the Scope of the Seventh Batch of Nationally Organized Centralized Purchase of Drugs", requiring medical institutions to start reporting volumes on January 26, and at 24:24 on February 16: Submit data before 00 .
-
Another year of "315", are the pharmaceutical machine companies still on pins and needles?
Time of Update: 2022-04-15
However, compared with imported equipment, domestic pharmaceutical machine companies still need to continue to increase investment in research and development, improve the level of innovation, quality, and after-sales service, etc.
-
Recently, pharmaceutical companies are starting the pace of intensive listing!
Time of Update: 2022-04-15
In addition, according to the "Initial Public Offering of Stocks on the Science and Technology Innovation Board Listing Announcement" previously issued by First Pharmaceutical Holdings, it will also be listed on the Shanghai Stock Exchange on March 23, 2022, at a price of 39.